Study confirms efficacy of Infiltrator catheter:
This article was originally published in Clinica
A trial of Interventional Technologies' Infiltrator drug delivery catheter has demonstrated the safety and feasibility of using the device to deliver dilute ethanol in patients with in-stent restenosis. The Beaumont Alcohol Restenosis Study (BARS), which is assessing the procedure as a treatment for preventing in-stent restenosis, evaluated 24 patients with clinical evidence of ischaemia and diffuse in-stent restenosis. The patients received 15% ethanol delivered via the Infiltrator catheter. Procedural success was 100%, according to the San Diego, California company, with no major adverse in-hospital cardiac events. The study will now assess a further 25 patients who will receive 30% ethanol.